Mechanisms of PDAC Subtype Heterogeneity and Therapy Response
Investigators discuss how two different types of PDAC, basal-like type and classical type, interact with stromal and immune components of the microenvironment to impact prognosis and therapeutic outcomes.
[Bellerophon Therapeutics, Inc.] Bellerophon Therapeutics, Inc. announced that the FDA has accepted the company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase III trial of INOpulse® for the treatment of fibrotic interstitial lung disease.
[Nature Communications] Researchers determined transcriptional changes of idiopathic pulmonary fibrosis-airway basal cells and their potential profibrotic properties using a 3D culture system and novel mouse xenograft models.
[JCI Insight] Investigators found that growth factor–β1-mediated upregulation of UHRF1 repressed Beclin1 via promoter methylation induction which resulted in fibroblast activation and lung fibrosis both in vitro and in vivo.